Citi Downgrades Juno To Neutral, Says Potential Takeover Priced In
January 18, 2018 at 07:24 AM EST
Citi analyst Robyn Karnauskas last night downgraded Juno Therapeutics to Neutral from Buy while raising her price target for the shares to $81 from $59.
